Lexaria Bioscience Corp LEXX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LEXX is a good fit for your portfolio.
News
-
Lexaria's Investigational New Drug Application Filing Update
-
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
-
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
-
Lexaria Granted Two New Patents in Canada
-
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
-
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Trading Information
- Previous Close Price
- $1.35
- Day Range
- $1.34–1.43
- 52-Week Range
- $0.65–3.60
- Bid/Ask
- $1.33 / $1.40
- Market Cap
- $14.39 Mil
- Volume/Avg
- 5,077 / 117,536
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 39.47
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
Valuation
|
Metric
|
LEXX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.59 |
Price/Sales | 39.47 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LEXX
|
|---|---|
Quick Ratio | 6.17 |
Current Ratio | 8.22 |
Interest Coverage | — |
Quick Ratio
LEXX
Profitability
|
Metric
|
LEXX
|
|---|---|
Return on Assets (Normalized) | −114.11% |
Return on Equity (Normalized) | −116.69% |
Return on Invested Capital (Normalized) | −123.29% |
Return on Assets
LEXX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xfdy | $431.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ypmdfw | $91.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cgkrz | $90.2 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Hspxzs | $41.3 Bil | |
MRNA
| Moderna Inc | Tdvc | $30.6 Bil | |
ARGX
| argenx SE ADR | Rbnf | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Tnpd | $24.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fvhqgmd | $21.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hhcvdc | $17.5 Bil | |
INCY
| Incyte Corp | Ryjyq | $12.3 Bil |